July 17, 2025 | Aclymate, Carbon Emissions, Carbon footprint, Hybrid Events, Hybrid meetings, Impetus Digital, Pharma meetings, Sustainability, carbon neutral, green pharma, pharma vvents, reduce carbon, sustainable pharma
Impetus Digital was promoted to the Aclymate Silver Tier for their efforts in crafting carbon-neutral virtual and live meetings for life science companies.

A year after Impetus Digital first calculated and offset all of our home office-related emissions, we’re excited to announce that we have now implemented Phase 2 of our journey toward carbon neutrality. As of January 2024, all of the carbon emissions associated with Impetus Digital staff attending hybrid meetings live (i.e., flights, ground transportation for local meetings, and accommodation) have been–and will continue to be–offset. This means that–while we still encourage clients to go fully virtual to cut down on their meeting-associated emissions almost entirely–those opting for a hybrid event can still feel good knowing that any Impetus support staff attending the meeting in person is not contributing to the carbon footprint of the event.
In fact, we were recently promoted to the Aclymate Silver Tier for our efforts to date. Plus, we continue to be platinum-certified by the Green Business Benchmark (GBB), demonstrating our commitment to sustainable practices!
Phase 3 and beyond will involve calculating and offsetting the emissions associated with the actual meeting venues, any Impetus business trips for reasons other than attending live client meetings and events (e.g., conference attendance), and the small but non-negligible emissions associated with our online portals. Stay tuned for more updates!
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
Phil Hirsh, PhD, Founder & Chief Executive at Synergia Integrated teleBehavioral Health; and Craig Wright, MD, Senior Physician Executive and Consultant, discuss a range of topics surrounding telemedicine and other digital health…
Frank Armenante, Director of Commercial Execution at Novo Nordisk, discusses a range of topics, from the impact of COVID-19 on commercial operations and the digitization of Pharma to his leadership lessons…
Even after the pandemic is long behind us, virtual collaboration will become mainstay in Pharma.
Brian Canestraro, General Manager at Intercept Pharmaceuticals, discusses a range of hot topics, from Brian’s leadership lessons and tips to the impact of the COVID-19 pandemic on the way that Pharma…
Curtis Khan, CEO and Founder of BookJane, discusses the ongoing caregiver crisis and how BookJane’s solutions and other digital technologies can help to close this gap. We also delve into how…
Ramsay Brown, CEO and Founder of Quol, delves into several different HealthTech topics, including the concept of VR therapeutics and the importance of incorporating behavioral science and neuroscience into VR solutions, as…
Rodney Hu, founder of 209|Digital and a popular podcast host. We explore Rodney’s work within the HealthTech space and what he believes has to happen for the healthcare industry to more…
Sandra Graham-Mason, Director of Marketing at Regeneron Pharmaceuticals discusses a variety of topics, from the impact of COVID-19 on the way that Pharma teams interact with internal stakeholders and KOLs to…
Dr. Phillip Alvelda, CEO and Co-Founder of Brainworks, discusses all things artificial intelligence and machine learning. We also explore the concepts of whole-brain AI systems and ambient biometrics, and how AI-enhanced vital…
Learn how our client successfully carried out a set of three virtual plan of action (POA) discussions, including one internal “Fishbowl” web meeting.


